- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Topical Beremagene Geperpavec, Placebo
- Biological · Other
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
- Interventions
- EB-101 Surgical application of RDEB wounds
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin Sulfate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive
- Interventions
- FCX-007
- Genetic
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- allo-APZ2-EB
- Biological
- Lead sponsor
- RHEACELL GmbH & Co. KG
- Industry
- Eligibility
- 0 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- PTR-01, Normal saline
- Drug
- Lead sponsor
- Phoenix Tissue Repair, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Redwood City, California • Aurora, Colorado • Philadelphia, Pennsylvania